Collagen Solutions PLC Medical Research Studentship
September 22 2015 - 1:01AM
RNS Non-Regulatory
TIDMCOS
Collagen Solutions PLC
22 September 2015
22 September 2015
Collagen Solutions Plc
Awarded Medical Research Scotland Ph.D. Studentship
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of medical grade collagen components for use in
regenerative medicine, medical devices and in-vitro diagnostics,
announces that it has been awarded a Medical Research Scotland
Ph.D. studentship in partnership with the University of
Strathclyde.
The project titled "Improving control over the mechanical and
transport properties of collagen-based scaffolds for tissue
engineering and regenerative medicine" will be delivered by the
University of Strathclyde and Collagen Solutions plc and is one of
only 13 four-year PhD Studentships funded by Medical Research
Scotland this year. (http://www.medicalresearchscotland.org.uk)
Collagen, the most widely used matrix for Tissue Engineering and
Regenerative Medicine, undergoes a constant process of remodelling
in the body, and the balance of its degradation by the cells of the
body with new collagen synthesis determines its strength and
integrity over time. Thus, there is a clear need for safe and
effective methods to control the rate implanted collagen is
degraded.
Using a cell culture model researchers at the University of
Strathclyde have discovered that, by treating collagen with
existing clinically-approved drugs, they are able to slow down the
rate at which collagen scaffolds are degraded. This project will
provide further insight into the potential for a wider range of
drugs of this class to manipulate collagen degradation profiles.
Methods for characterising the mechanical properties of
collagen-based scaffolds will also be improved. Working with staff
from Collagen Solutions, the data will ultimately be used to design
novel collagen-based products for the medical devices market and
regenerative medicine markets.
Dr Stewart White, Chief Executive Officer of Collagen Solutions
plc said: "This studentship is further recognition of the expertise
that Collagen Solutions has in the development and manufacture of a
wide range of medical grade collagen based products for use in
novel regenerative medicine products. The rapid application of new
methods for the design and preservation of novel collagen scaffolds
will generate applications for collagen materials where our
know-how can be applied to and commercialised with significant
benefits for patients."
Enquiries:
Collagen Solutions Plc
David Evans, Chairman Tel: 07740 084 452
Stewart White, CEO Tel: 0141 648 9100
Panmure Gordon & Co (Nomad and Tel: 020 7886 2714
Broker) Tel: 020 7886 2905
Robert Naylor (Corporate Finance)
Maisie Atkinson (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001
Note to Editors:
Background to Research Project:
Biomedical materials and artificial tissues are being developed
to repair, replace and enhance natural tissues; these must maintain
sufficient strength and stability following implantation. Collagen,
the widely used matrix for tissue engineering, is constantly being
re-modelled in the body, and the balance of its degradation by the
cells of the body and new collagen synthesis determines its
strength and integrity over time. There is a clear need for safe
and effective methods to control the rate at which implanted
collagen is degraded.
Using a cell culture model, researchers at the University of
Strathclyde have discovered a safe method to slow down the rate at
which collagen scaffolds degrade. Collagen hydrogels seeded with
cells and treated with existing clinically approved drugs
demonstrated increased stiffness compared with untreated cell
seeded hydrogels over time in culture.
The work will entail cell culture, fluorescence microscopy, SEM,
mechanical testing and mathematical modelling of the physical
properties of hydrogels (BOSE mechanical testing devices),
pharmaceutical analysis of both drugs and peptides. The facilities
and research environment in the host department were judged best in
Scotland, and 4th in the UK, in the recent REF analysis, and the
student will join a department with a vibrant atmosphere - host to
a community of approximately 120 postgraduate research
students.
This project will enable us to gain insight into the potential
for further drugs of this class to inhibit collagen degradation,
determine the mechanism(s) of action, and investigate the retention
of the drugs in the collagen matrix. During the course of the work
the methods for measuring mechanical properties of hydrogels will
be improved. Working with Collagen Solutions plc, the data will
ultimately be used to design novel collagen-based products for the
medical devices market.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFLIATILFIE
(END) Dow Jones Newswires
September 22, 2015 02:01 ET (06:01 GMT)
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jul 2023 to Jul 2024